This registry study demonstrates that ERT-naïve infants and children with ADA-SCID (EN group) attained and maintained optimal plasma ADA activity, increased lymphocyte counts, and had manageable infection rates with no mortality while being treated with elapegademase for up to 30 months. The gene discussed is ADA; the disease is infection.